PPCB Stock Summary and Trading Ideas (Propanc Biopharma | NASDAQ:PPCB)

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

Propanc Biopharma trades on the NASDAQ stock market under the symbol PPCB.

As of August 25, 2026, PPCB stock price declined to $1.13 with 8,874 million shares trading.

PPCB has a beta of 2.26, meaning it tends to be more sensitive to market movements. PPCB has a correlation of 0.06 to the broad based SPY ETF.

PPCB has a market cap of $2.57 million. This is considered a Sub-Micro Cap stock.

PPCB has underperformed the market in the last year with a price return of -98.7% while the SPY ETF gained +19.9%. PPCB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.8% and -1.7%, respectively, while the SPY returned +3.0% and -0.9%, respectively.

PPCB support price is $1.05 and resistance is $1.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PPCB shares will trade within this expected range on the day.